NCT05585034View on ClinicalTrials.gov

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

May 20, 2025

Study Completion Date

May 20, 2025

Conditions
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamousUrothelial CarcinomaRenal Cell Carcinoma, Clear CellCastration-resistant Prostate CancerOvarian Cancer, EpithelialTNBC - Triple-Negative Breast CancerColorectal Cancer
Interventions
BIOLOGICAL

XmAb®808

Monoclonal bispecific antibody

BIOLOGICAL

Keytruda® (pembrolizumab)

Monoclonal antibody

Trial Locations (12)

10032

Columbia University Irvine Medical Center, New York

15213

UPMC Hillman Cancer Center, Pittsburgh

30322

Winship Cancer Institute, Emory University, Atlanta

34232

Florida Cancer Specialists, Sarasota

37203

Tennessee Oncology, Nashville

45219

University of Cincinnati Medical Center, Cincinnati

53226

Froedtert Hospital & The Medical College of Wisconsin, Milwaukee

60611

Northwestern Memorial Hospital, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute at HealthONE, Denver

84112

Huntsman Cancer Institute, University of Utah, Salt Lake City

90095

UCLA Hematology/Oncology, Los Angeles

All Listed Sponsors
lead

Xencor, Inc.

INDUSTRY